Uncovering key targets of success for immunotherapy in pancreatic cancer

• DOI: 10.1080/14728222.2021.2010044
• Publication Date: 2021-11-22T10:38:21Z
• Authors: Andrea Pretta; Eleonora Lai; Mara Persano; Clelia Donisi; Giovanna Pinna; Erika Cimbro; Alissa Parrino; Dario Spanu; Stefano Mariani; Nicole Liscia; Marco Dubois; Marco Migliari; Valentino Impera; Giorgio Saba; Valeria Pusceddu; Marco Puzzoni; Pina Ziranu; Mario Scartozzi
• Keywords: Cancer Immunotherapy

Introduction Despite available treatment options, pancreatic ductal adenocarcinoma (PDAC) is frequently lethal. Recent immunotherapy strategies have failed to yield any notable impact. Therefore, research focussed on unearthing new drug targets and therapeutic tackle this malignancy attain more positive outcomes for patients.Areas covered In perspective article, we evaluate the main resistance mechanisms immune checkpoint inhibitors (ICIs) approaches circumvent them. We also offer an assessment of concluded ongoing trials PDAC immunotherapy. Literature was performed Pubmed accessible through keywords such as: 'pancreatic adenocarcinoma,' 'immunotherapy,' 'immunotherapy resistance,' 'immune escape,' 'biomarkers.' Papers published between 2000 2021 were selected.Expert opinion The tumor microenvironment a critical variable because its role as physical barrier inhibitory signaling. Promising appear be combination immunotherapeutics with other targeted treatments. Going forward, predictive biomarkers are required improve patient selection. Biomarker-driven could enhance assessing in PDAC.